Overview

A Study to Evaluate the Efficacy and Safety of Simtuzumab Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

This study will compare the efficacy of simtuzumab (GS-6624) versus placebo in combination with gemcitabine in adults with pancreatic cancer. The treatment phase of this study will be comprised of 2 sequential parts: an open label treatment phase and a double-blinded treatment phase.

Phase:

Phase 2

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Gemcitabine